Low-Dose Atropine and the FDA: What the SYD-101 Panel Means

On October 30, 2026, the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee meets to review SYD-101, Sydnexis’s 0.01% atropine eye drop for slowing myopia progression in children. The committee gives advice; the FDA makes the decision. Whatever it recommends, the practical question for a practice is the same: can you show, visit by visit, how each child’s myopia is changing and what you did about it? This guide explains what the panel is reviewing, what US practices use today, and how to run a myopia-management service that holds up under either outcome.

This is a practice-operations guide, not medical advice. Treatment decisions belong to the prescribing clinician and the child’s family.

What is the FDA panel reviewing on October 30?

The committee is reviewing new drug application (NDA) 219694: atropine sulfate ophthalmic solution 0.01%, proposed for slowing myopia progression in children aged 3 and older. The meeting is in the Federal Register notice (docket FDA-2026-N-10606) and includes an open public hearing, where clinicians and families can speak.

The data come mainly from STAR, a phase 3 trial of 847 children aged 3 to 14. The primary endpoint was the share of children whose myopia progressed by more than 0.75 dioptres (D) by month 36. Optometry Times reports that the 0.01% dose met that endpoint against placebo drops (P = .0226), and also met the annual progression-rate endpoint.

Why did the FDA turn SYD-101 down in 2025?

In October 2025 the FDA issued a complete response letter, the formal “not approved as submitted” decision. It accepted that the primary endpoint was met. But, as Healio reported, the agency said the data “collectively suggest limited to no clinical benefit with questionable durability and robustness of the treatment effect.” No safety or manufacturing problems were cited.

Sydnexis filed a formal dispute resolution request. In July 2026 the FDA said it would convene an advisory committee, and the October 30 date followed in September. Europe reached a different view: the same formulation was authorized in the EU on 2 June 2025 as Ryjunea, for children aged 3 to 14, and is marketed by Santen. It is also approved in the UK.

What could the panel recommend, and what happens next?

An advisory committee does not approve anything. The FDA’s own guidance says the agency “makes the final decisions” and weighs the advice it receives. Broadly, three paths are open:

• A favourable discussion or vote. The FDA may still ask for more data, but approval becomes a realistic prospect.
• An unfavourable one. The 2025 position stands, and US prescribers continue with compounded atropine.
• A split or conditional view. For example, support for a narrower group of children, such as fast progressors. Labeling would then matter as much as approval.

We will not guess the outcome. We will update this guide after the meeting.

What US practices use today

No atropine drop is FDA-approved for slowing myopia in children today. Practices that prescribe it use compounded atropine. Under the FDA’s own rules, compounded drugs are not FDA-approved, so the agency does not verify their safety, effectiveness or quality before they are sold. Families usually pay out of pocket.

Several devices do carry FDA authorization for myopia control:

• MiSight 1 day soft contact lenses, approved in November 2019 for children aged 8 to 12 at the start of treatment.
• Acuvue Abiliti Overnight orthokeratology (ortho-k) lenses, approved in May 2021 for myopia management. Check each ortho-k lens’s labeling: some are approved only for temporary reduction of myopia, not for slowing its progression.
• Essilor Stellest spectacle lenses, authorized on September 25, 2025 for children aged 6 to 12 at the start of treatment.

Many practices combine these. Fitting and reordering specialty lenses is its own workflow; our guide to contact lens fitting software covers the ortho-k and soft-lens side.

How to run a myopia-management service

Whichever treatment a child is on, the service depends on the same records. Software either keeps them in one place or leaves them scattered across notes, spreadsheets and pharmacy faxes.

Measure the same things every visit

Record cycloplegic refraction and axial length at baseline and at every review, with the device, the eye and the date. The International Myopia Institute guidance, summarised by the BCLA, calls for annual cycloplegic refraction and says axial length is preferable on top, particularly with ortho-k and drug treatments. Axial length usually comes from an optical biometer; topographers matter too for ortho-k fits, as our comparison of corneal topography software explains.

Chart progression, not just the latest result

A single reading tells you little. A chart of axial length and refraction against age shows whether treatment is working. It also gives parents something concrete to look at.

Set recall by protocol, not memory

The IMI report ties review frequency to the treatment chosen. Whatever interval your protocol sets, the system should book it and chase missed visits. A child who drops out of follow-up is the most common silent failure. Our review of patient recall systems for optometry compares tools that automate this.

Document consent for compounded or off-label use

Where you prescribe compounded atropine, record what the family was told: the drug is compounded and not FDA-approved, the expected benefit is uncertain, the possible side effects, and the cost. Store the signed consent with the chart. Your malpractice carrier and state board are the right sources for the exact wording.

Track the compounding pharmacy loop

Log which pharmacy filled each prescription, the concentration, the fill date and the refill due date. If a product is approved later, the same log shows which families to contact about switching.

Talk to parents in numbers they can follow

Share the progression chart at each visit. Explain that treatment aims to slow change, not reverse it. Send reminders for drops, lens wear and appointments through the channel each family actually reads.

What to look for in software

• Structured fields for axial length and cycloplegic refraction, per eye, with trend charts over time.
• Treatment history that records each change: drug and concentration, lens type, start and stop dates.
• Recall rules per treatment, with automated reminders and a list of overdue patients.
• Consent forms stored against the patient and the prescription.
• Prescription and pharmacy tracking for compounded drops, with refill reminders.
• A parent-facing summary or portal view of the progression chart.

Ask each vendor to show these working on a sample patient with three years of data. A demo with one visit hides whether the charts are useful.

What to do before and after October 30

If you run a myopia service today, the work does not depend on the vote. Clean up your measurement records, set recall by protocol, and make sure every family on compounded atropine has a consent on file. If the FDA later approves a product, those records tell you who to contact first. If it does not, they are still what good care and good documentation require.

For the specialty-lens side of the same service, read our contact lens fitting software guide next.